PE20080845A1 - METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS - Google Patents

METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS

Info

Publication number
PE20080845A1
PE20080845A1 PE2007001268A PE2007001268A PE20080845A1 PE 20080845 A1 PE20080845 A1 PE 20080845A1 PE 2007001268 A PE2007001268 A PE 2007001268A PE 2007001268 A PE2007001268 A PE 2007001268A PE 20080845 A1 PE20080845 A1 PE 20080845A1
Authority
PE
Peru
Prior art keywords
active agents
pharmacologically active
tablets containing
containing pharmacologically
manufacturing tablets
Prior art date
Application number
PE2007001268A
Other languages
Spanish (es)
Inventor
Anasuya Ashok Ghosh
Yatindra Joshi
Shoufeng Li
Alan Edward Royce
Colleen Ruegger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080845A1 publication Critical patent/PE20080845A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONSTA DE UN LUBRICANTE EXTERNO TAL COMO ESTEARATO DE MAGNESIO O CALCIO, FUMARATO DE SODIO,LAURIL-SULFATO DE SODIO, ENTRE OTROS, PARA LA COMPACTACION DE UNA MEZCLA QUE CONTIENE: a) UN PRINCIPIO ACTIVO TAL COMO PROTEINA, POLIPEPTIDO, HORMONA, POLISACARIDO, CARBOHIDRATO, LIPIDO, O UNA COMBINACION DE LOS MISMOS; b) UN AGENTE DE SUMINISTRO, COMO, ACIDO N-(5-CLORO-SALICILOIL)-8-AMINO-CAPRILICO (5-CNAC), ACIDO N-(10-[2-HIDROXI-BENZOIL]-AMINO)-DECANOICO (SNAD), ACIDO N-(8-[2-HIDROXI-BENZOIL]-AMINO)-CAPRILICO (SNAC), O UNA COMBINACION DE LOS MISMOS. DICHA COMPOSICION HACE REFERENCIA A UNA MEJORA EN LAS PROPIEDADES FISICAS DE LA TABLETA TALES COMO, DUREZA, TIEMPO DE DESINTEGRACION Y DISOLUCIONIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT CONSISTS OF AN EXTERNAL LUBRICANT SUCH AS MAGNESIUM OR CALCIUM STEARATE, SODIUM FUMARATE, SODIUM LAURYL-SULPHATE, AMONG OTHERS, FOR THE COMPACTION OF A MIXTURE THAT CONTAINS: a) AN ACTIVE PRINCIPLE AS PROTEIN: a) , POLYPEPTIDE, HORMONE, POLYSACCHARIDE, CARBOHYDRATE, LIPID, OR A COMBINATION OF THEM; ( SNAD), N- (8- [2-HYDROXY-BENZOYL] -AMINE) -CAPRYLIC ACID (SNAC), OR A COMBINATION OF THEM. SAID COMPOSITION REFERS TO AN IMPROVEMENT IN THE PHYSICAL PROPERTIES OF THE TABLET SUCH AS HARDNESS, DISINTEGRATION TIME AND DISSOLUTION

PE2007001268A 2006-09-22 2007-09-20 METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS PE20080845A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82659706P 2006-09-22 2006-09-22

Publications (1)

Publication Number Publication Date
PE20080845A1 true PE20080845A1 (en) 2008-08-13

Family

ID=39227036

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001268A PE20080845A1 (en) 2006-09-22 2007-09-20 METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS

Country Status (5)

Country Link
AR (1) AR062925A1 (en)
CL (1) CL2007002724A1 (en)
PE (1) PE20080845A1 (en)
TW (1) TW200820993A (en)
WO (1) WO2008039351A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3326620T1 (en) 2010-12-16 2020-07-31 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
JP6022538B2 (en) 2011-04-12 2016-11-09 ノヴォ ノルディスク アー/エス Double acylated GLP-1 derivative
PT2827845T (en) 2012-03-22 2019-03-29 Novo Nordisk As Compositions comprising a delivery agent and preparation thereof
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
CN104203221A (en) 2012-03-22 2014-12-10 诺和诺德A/S(股份有限公司) Compositions comprising a delivery agent and preparation thereof
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
MX2020007598A (en) 2018-02-02 2020-09-03 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4568426B2 (en) * 1998-04-08 2010-10-27 協和発酵キリン株式会社 Tablet manufacturing method and tablet
AU2004255458B2 (en) * 2003-07-11 2007-09-13 Emisphere Technologies, Inc. Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Also Published As

Publication number Publication date
WO2008039351A2 (en) 2008-04-03
CL2007002724A1 (en) 2008-05-16
WO2008039351A3 (en) 2008-06-19
TW200820993A (en) 2008-05-16
AR062925A1 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
PE20080845A1 (en) METHOD FOR MANUFACTURING TABLETS CONTAINING PHARMACOLOGICALLY ACTIVE AGENTS
CO6160317A2 (en) NON-HANDLING PHARMACEUTICAL DOSAGE FORMS THAT INCLUDE AN OPIOID ANALGESIC
AR037490A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES
EA200801926A1 (en) TABLETS OF PARACETAMOL WITH FAST DELIVERY
AR027391A1 (en) BOTULIN TOXIN PHARMACEUTICAL COMPOSITIONS
UY30535A1 (en) COMPOSITION UNDERSTANDING ANTIRRETROVIRAL PHARMACOS AND AT LEAST AN INSOLUBLE WATER POLYMER, PREPARATION PROCESS AND APPLICATIONS.
PE20061017A1 (en) PHARMACEUTICAL FORMULATION BY DIRECT COMPRESSION OF A DIPEPTIDIL-PEPTIDASE IV INHIBITOR AND PROCESS
MX2009003030A (en) Galenic form for the trans-mucosal delivery of active ingredients.
ECSP088490A (en) ORAL PHARMACEUTICAL FORM THAT CONTAINS AS ACTIVE PRINCIPLES A PROTON PUMP INHIBITOR TOGETHER WITH ACETILSALICYL ACID
PA8559501A1 (en) PHARMACEUTICAL FORMULATIONS OF 5,7,14-TRIAZATETRACICLO [10.3.1.02,11.04,9] -HEXADECA-2 (11), 3,5,7,9-PENTAENO
ATE493973T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
AR057946A1 (en) FORMULATION OF SUSTAINED RELEASE ZONISAMIDE
CO6280475A2 (en) METHOD TO TREAT THE DEFICIENCY OF VITAMIN B12
CL2007003356A1 (en) COMPOUNDS DERIVED FROM BENZOPIRAZOLES; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE FOR THE TREATMENT OF ASTHMA, INFLAMMATION, AMONG OTHER DISEASES.
CO6460753A2 (en) PROCEDURE AND COMPOSITION TO IMPROVE THE ABSORPTION OF THERAPEUTIC AGENTS
CL2004000899A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING TELMISARTAN SODIUM SALT AND A DIURETIC AGENT AND PREPARATION PROCEDURE.
AR063538A1 (en) TREATMENT OF PARKINSON'S DISEASE
DK1608346T3 (en) Drug delivery compositions of alpha-hydroxy acid ester and methods of use thereof
AR061790A1 (en) SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, FORMULATIONS OF IMMEDIATE RELEASE TABLETS OF A THROMBIN RECEIVER ANTAGONIST, AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT
PE20230819A1 (en) COMPOSITIONS AND USES OF GLP-1
AR061166A1 (en) PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF PHENYLPHERINE
ECSP044961A (en) ACID N- (5-CHLOROSALICILOIL) -8-AMINOCAPRILICO AS AN ORAL SUPPLY AGENT FOR PARTIROID HORMONE FRAGMENTS
AR046036A1 (en) RISEDRONATE COMPOSITIONS AND METHODS FOR USE
AR048672A1 (en) DISINTEGRATION TABLETS THAT INCLUDE LICARBAZEPINA
AR036085A1 (en) DOSAGE FORMS AND PROCEDURE FOR MANUFACTURING

Legal Events

Date Code Title Description
FA Abandonment or withdrawal